<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806777</url>
  </required_header>
  <id_info>
    <org_study_id>H18-02794</org_study_id>
    <nct_id>NCT03806777</nct_id>
  </id_info>
  <brief_title>Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging</brief_title>
  <acronym>DexmedMRI</acronym>
  <official_title>Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Columbia Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the use of intranasal dexmedetomidine (IN-dex) as a sole agent in&#xD;
      aiding the successful completion of a MRI scans in children. Dexmedetomidine, a routinely&#xD;
      used anesthetic agent in our institution, has many benefits including sedation with&#xD;
      neuro-protective and respiratory sparing features. We will test its effectiveness in&#xD;
      completing MRI scans in children that would otherwise be given a full general anesthetic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:&#xD;
&#xD;
      To assess the use of IN-dex as a sole agent in aiding the successful completion of a MRI scan&#xD;
      in children.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      We hypothesize that the optimal dose for IN-dex to produce appropriate sedation for MRI will&#xD;
      be between 1 and 3 mcg/kg. We also hypothesize that this dose will be lower in the older age&#xD;
      group.&#xD;
&#xD;
      Justification:&#xD;
&#xD;
      The dose required for IN-dex to enable safe sedation for MRI scanning as a sole agent is&#xD;
      undetermined at present. This study will enable us to find the optimal dose for effective&#xD;
      sedation for MRI scanning in a range of age groups. This will avoid the need for propofol and&#xD;
      remifentanil general anesthesia (that is the current standard of care) in this group of&#xD;
      patients. Our motivation for avoiding general anesthesia is that there is ongoing concern&#xD;
      that general anesthesia causes long term neurocognitive effects in children. Finally,&#xD;
      identifying a safe yet effective dose of IN-dex, which can be nurse-administered, will also&#xD;
      allow us to improve access to MRI scans that are limited by the access to general anesthesia.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. To determine the dose of IN-dex that, when used as a sole agent, produces minimal to&#xD;
           moderate sedation that is adequate for successful completion of MRI in children with&#xD;
           &gt;90% effectiveness.&#xD;
&#xD;
        2. To explore the logistics of a nurse-administered sedation protocol to increase access to&#xD;
           the MRI.&#xD;
&#xD;
      Research Design:&#xD;
&#xD;
      We propose a dose finding study of IN-dex using the biased coin design (BCD) method in three&#xD;
      different age groups (3 to &lt;8 years, 8 to &lt;12 years, 12 to &lt;19 years). The study specific&#xD;
      interventions will include identification of children appropriate for the study following&#xD;
      detailed assessment using a scoring system developed by our Child Life specialists for use at&#xD;
      their MRI preparation session.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      The dose of IN-Dex that produces mild to moderate sedation in 90% of subjects will be&#xD;
      calculated using the pooled adjacent violators algorithm (PAVA) and bootstrap methods will be&#xD;
      used to calculate the 95% confidence limits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose finding</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose</measure>
    <time_frame>Immediately after completion of the MRI scan.</time_frame>
    <description>The intranasal dexmedetomidine dose in mcg/kg that produces successful completion of MRI scan with acceptable MRI image quality in 90% of individuals (ED 90).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uninterrupted scans</measure>
    <time_frame>Immediately after completion of the MRI scan.</time_frame>
    <description>Total number of scans that were able to be completed without interruptions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respirator support</measure>
    <time_frame>During MRI scan</time_frame>
    <description>Total number of occurrences of respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During MRI scan</time_frame>
    <description>Occurrence of haemodynamic disturbance (bradycardia: absolute heart rate ≤ 40 bpm, hypertension: relative mean arterial pressure ≥ 50% baseline, hypotension: relative mean arterial pressure ≤ 50% baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Yale Preoperative Anxiety Scale (mYPAS)</measure>
    <time_frame>Immediately before administration of intranasal dexmedetomidine</time_frame>
    <description>Pre-procedure mYPAS score. The scale is a total summed score (4-22) of 5 areas; Activity (1-4), Vocalizations (1-6), Emotional expressivity (1-4), state of apparent arousal (1-4), and use of parents (1-4). A lower score represents a lower level of anxiety.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>MRI Sedation</condition>
  <arm_group>
    <arm_group_label>Intra-nasal dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of dexmedetomidine, determined by a biased coin algorithm (min: 1 mcg/kg; max: 4 mcg/kg or 200mcg), will be delivered intranasally 45min before an MRI scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Highly selective alpha-2 adrenergic agonist with sedative properties.</description>
    <arm_group_label>Intra-nasal dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA 1 or 2&#xD;
&#xD;
          -  Scheduled for elective MRI scan on the general anesthesia list&#xD;
&#xD;
          -  Child Life MRI simulation score of 6-10 (Figure 1)&#xD;
&#xD;
          -  Age 3 - 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking existing opioid, sedative, or cannabinoid medication&#xD;
&#xD;
          -  Severe learning disability defined as the inability to follow simple commands&#xD;
&#xD;
          -  Severe Cardiac disease&#xD;
&#xD;
          -  Chronic hypertension&#xD;
&#xD;
          -  Allergy to dexmedetomidine&#xD;
&#xD;
          -  Nasal anatomical abnormality&#xD;
&#xD;
          -  Known or anticipated difficult airway&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ansermino, FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Children's Hospital, Department of Anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew K Poznikoff, BSc</last_name>
    <phone>604-875-2000</phone>
    <phone_ext>1989</phone_ext>
    <email>andrew.poznikoff@cw.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Ansermino, FRCA</last_name>
    <phone>604-875-2711</phone>
    <email>mansermino@cw.bc.ca</email>
  </overall_contact_backup>
  <link>
    <url>http://part.bcchr.ca</url>
    <description>Pediatric Anesthesia Research Team website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Mark Ansermino</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

